Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Dipeptidyl Peptidase 3 (DPP3) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DPP3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DPP3 Mutant / Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View DPP3 Products |
| Gene Delivery | DPP3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View DPP3 Products |
| Benchmark Ab | Anti-DPP3 Antibody Recombinant positive control. |
View DPP3 Products |
| Validator | DPP3 siRNA Set For knockdown verification. |
View DPP3 Products |
| Related Target A | DPP4 Crucial for selectivity counter-screening against other dipeptidyl peptidases. |
View DPP4 Products |
| Related Target B | KEAP1 DPP3 interacts with KEAP1, activating the NRF2 antioxidant pathway in cancers. |
View KEAP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter screening | Homolog panel proteins (DPP4, DPP8, DPP9) strictly verified by mass spec and purity |
| Enzymatic Activity Preservation | HEK293 Expressed proteins ensuring native folding and optimal baseline activity |
| Lack of Controls | Benchmark Antibodies included for standardized assay normalization |
| False Positives | Validated siRNA included for specificity checks in cell-based assays |
Live DPP3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DPP3 therapeutics is emerging, with major players investigating its role beyond traditional peptide metabolism. As a critical modulator of the NRF2/KEAP1 pathway and angiotensin/enkephalin degradation, DPP3 is becoming a dual-action target for pain management, cardiovascular disease, and refractory solid tumors. As first-generation small molecule inhibitors reach early evaluation, the next wave of R&D is targeting highly selective inhibition to avoid cross-reactivity with the widely targeted DPP4.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic Spin-offs, Biotech | Pain Management, Heart Failure | Selectivity Assay (Need High-Purity WT and Homolog Proteins) |
| Targeted Protein Degrader (PROTAC) | Emerging Platforms | Solid Tumors (NRF2 Addicted) | Ternary Complex Validation (Need Sequence-Verified Recombinant Proteins) |
| Monoclonal Antibody | Early Stage Biotech | Cancer Diagnostics / Targeting | Binding Affinity (Need ECD/Full-length Native Protein) |